Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Century Therapeutics ( (IPSC) ) is now available.
On July 1, 2025, Century Therapeutics‘ Board of Directors approved a significant reduction in force, cutting approximately 51% of its workforce to concentrate on high-potential programs. The company anticipates incurring around $3.7 million in severance and related costs, with the reduction expected to be largely completed by the end of the third quarter of 2025.
The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
Spark’s Take on IPSC Stock
According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.
Century Therapeutics shows promising revenue growth but struggles with profitability and cash flow efficiency. Technical trends are weak, indicating bearish sentiment. However, a positive corporate event and analyst sentiment provide some optimism.
To see Spark’s full report on IPSC stock, click here.
More about Century Therapeutics
Century Therapeutics, Inc. operates in the biotechnology industry, focusing on developing transformative therapies.
Average Trading Volume: 862,724
Technical Sentiment Signal: Sell
Current Market Cap: $47.83M
See more data about IPSC stock on TipRanks’ Stock Analysis page.